Back to Search
RISHITA SINGH
Behavior Technician
NPI: 1538043021Individual
Specialties, Licenses & Credentials
Behavior TechnicianPrimary
Behavior Technician
Code: 106S00000X
Clinical Trials (2)
2
Linked Trials
0
Recruiting
2
With Results
Research & Publications (6)
Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis.
PMID 31367468·Int J Retina Vitreous·2019
8-other
A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis.
PMID 26445522·Clin Ophthalmol·2015
8-other
A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis.
PMID 24836866·Br J Ophthalmol·2014
2-rct
Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema.
PMID 22423055·Br J Ophthalmol·2012
8-other
Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization.
PMID 12824270·Invest Ophthalmol Vis Sci·2003
7-preclinical
Vascular endothelial growth factor and the regulation of angiogenesis.
PMID 11036931·Recent Prog Horm Res·2000
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 100 N PACIFIC COAST HWY
EL SEGUNDO, CA 90245 - Phone
- (310) 856-0800
Quick Facts
- NPI
- 1538043021
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 2
- Publications
- 6
Are you this provider?
Claim Your Profile